• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

OKYO Pharma Limited - Ordinary Shares (NQ:OKYO)

2.320 +0.070 (+3.11%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 22,644
Open 2.260
Bid (Size) 2.160 (200)
Ask (Size) 2.400 (400)
Prev. Close 2.250
Today's Range 2.220 - 2.320
52wk Range 0.9016 - 3.349
Shares Outstanding N/A
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
OKYO Pharma Appoints Industry Veteran Robert J. Dempsey as Chief Executive Officer
January 05, 2026
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma to Ring the Opening Bell at Nasdaq
December 19, 2025
From OKYO Pharma LTD
Via GlobeNewswire

Performance

YTD
+4.0%
+4.0%
1 Month
+17.8%
+17.8%
3 Month
+10.5%
+10.5%
6 Month
-18.9%
-18.9%
1 Year
+80.5%
+80.5%

More News

Read More
News headline image
OKYO Pharma Announces Chairman and Founder Acquires Shares
December 15, 2025
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma Stock Rises After Company Outlines Development Pathway For Neuropathic Corneal Pain Drug ↗
September 22, 2025
Via Stocktwits
News headline image
OKYO Pharma Announces New Data Showing Favorable Corneal Nerve Outcomes in Phase 2 Study for Neuropathic Corneal Pain
December 11, 2025
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Announces Chairman and Founder Acquires Shares
December 03, 2025
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Announces Chairman and Founder Acquires Shares
November 21, 2025
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma to Present at OIS XV in San Diego
November 18, 2025
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma to Present at BIO-Europe 2025 in Vienna
October 29, 2025
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Announces Chairman and Founder Acquires Shares
October 16, 2025
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Announces Registration Pathway with 100 Patient Multi-Center Clinical Trial of Urcosimod in Neuropathic Corneal Pain
September 22, 2025
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Receives $1.9 Million in Non-Dilutive Funding to Accelerate Development of Urcosimod for Neuropathic Corneal Pain
July 17, 2025
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
July 17, 2025
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
July 16, 2025
Via Benzinga
News headline image
OKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain
July 16, 2025
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
July 15, 2025
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
June 16, 2025
Via Benzinga
News headline image
Goldman Small Cap Research Issues New Research Update on OKYO Pharma Limited
June 11, 2025
Via ACCESS Newswire
News headline image
OKYO Pharma to Present at the Bio International Convention
June 11, 2025
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma to Present at the GPCRs-Targeted Drug Discovery Summit
May 19, 2025
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
FDA Grants OKYO Pharma Fast Track Designation to Urcosimod for Neuropathic Corneal Pain
May 01, 2025
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Announces Plans to Accelerate the Clinical Development of Urcosimod to Treat Neuropathic Corneal Pain
April 30, 2025
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Announces Positive Data in Long-Term Stability of Urcosimod
March 31, 2025
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Files for Fast Track Designation with FDA for Urcosimod to Treat Neuropathic Corneal Pain
March 10, 2025
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Announces OK-101 Officially Assigned USAN : Urcosimod
February 12, 2025
From OKYO Pharma LTD
Via GlobeNewswire

Frequently Asked Questions

Is OKYO Pharma Limited - Ordinary Shares publicly traded?
Yes, OKYO Pharma Limited - Ordinary Shares is publicly traded.
What exchange does OKYO Pharma Limited - Ordinary Shares trade on?
OKYO Pharma Limited - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for OKYO Pharma Limited - Ordinary Shares?
The ticker symbol for OKYO Pharma Limited - Ordinary Shares is OKYO on the Nasdaq Stock Market
What is the current price of OKYO Pharma Limited - Ordinary Shares?
The current price of OKYO Pharma Limited - Ordinary Shares is 2.320
When was OKYO Pharma Limited - Ordinary Shares last traded?
The last trade of OKYO Pharma Limited - Ordinary Shares was at 01/08/26 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap